Aarti Industries (524208) Feb 2026 Filing Analysis

The project has moved beyond technology finalization into the equipment delivery and environmental clearance stage. (1 met across 1 tracked commitment)

Management targets a specific EBITDA range to be achieved within a three-year horizon. — target: ₹ 1,800-2,200 Cr (+4 more commitments)

Aarti is shifting its technical moat toward 'New Growth Avenues' including battery materials and sustainability platforms. (1 shifted, 4 expanding)

The company is aggressively expanding its cost moat through specific efficiency projects like the Back-Pressure Turbine (BPT) and Hybrid Power, aiming for an additional Rs 150-200 Cr in EBITDA from cost optimization alone by FY28. (3 expanding)

The segment is on a recovery path with a slight increase in revenue share, supported by strong export traction to the USA. (3 expanding, 1 contracting across 2 engines)

The Energy segment (MMA) saw volumes remain flattish due to plant disruptions and Indo-Pak conflict, but the company successfully expanded capacity from 200 KTPA to 260 KTPA to maintain global leadership. (4 expanding, 1 shifted across 2 engines)

The Pharma segment share has slightly decreased, but management expects positive developments from H1-FY26 due to domestic market share gains. (1 contracting, 2 expanding, 1 stable across 1 engine)

The MMA capacity expansion is progressing from a base of 23.1 KT in FY22 to 123 KT in FY25, with a massive jump to 260 KTPA scheduled for Q1 FY26. This represents a significant step-function growth in production capability. (5 accelerating across 5 signals, 3 leading indicators)

Aarti is investing in a new downstream project (PEDA) to integrate its ethylation products, which is expected to improve profit margins and capacity use.

The company is moving into a new phase of growth with the commissioning of Multi-Purpose Plants (MPP) and Zone 4 projects targeted for CY26, following the peak capex year of FY25. (1 new trend, 2 steady across 3 signals, 1 leading indicator)

The company has initiated execution for Multi-Purpose Plants (MPP) and Zone 4, with commissioning expected to drive growth between FY26 and FY28. (1 new trend, 1 accelerating across 2 signals, 1 leading indicator)

While FY25 EBITDA was muted at Rs. 1,016 Cr due to competitive pressures, the company is projecting a massive jump to Rs. 1,800-2,200 Cr by FY28, driven by operating leverage from new capacities. (2 accelerating, 1 reversing, 2 new trend across 5 signals)

The risk remains intensifying in terms of pricing. While volumes are recovering, overcapacity in China leads to 'marginal pricing' (selling at very low prices to cover basic costs), preventing an uptick in margins despite the end of destocking. (1 intensifying, 2 stable, 1 easing, 1 high-severity)

The risk is intensifying in terms of margin pressure. While volumes are growing, management notes that MMA margins are being compressed due to weak Gasoline-Naphtha cracks compared to FY24. (1 intensifying, 3 high-severity)

Margins were severely impacted this quarter by a 15-20% drop in key input prices (benzene/aniline), leading to Rs. 30 crore in inventory valuation losses. (3 intensifying, 2 stable, 1 high-severity)

The risk is intensifying in the short term due to higher freight costs. Exports rose to 55% of revenue, which increased 'other expenses' due to the freight component. However, working capital days are being managed toward a 70-80 day target. (4 intensifying, 1 easing)

The risk is STABLE as the company confirms that major projects like Zone 4 and the UPL JV are still in the commissioning/ramp-up phase with targets for CY26, confirming the long lead times previously identified. (2 stable, 3 intensifying)